Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT03477396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body. Ribociclib and aromatase inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study identification
- NCT ID
- NCT03477396
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- Aromatase Inhibitor Drug
- Laboratory Biomarker Analysis Other
- Pharmacokinetic Study Other
- Questionnaire Administration Other
- Ribociclib Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 70 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2018
- Primary completion
- Sep 28, 2021
- Completion
- Jun 4, 2023
- Last update posted
- Feb 19, 2024
2018 – 2023
United States locations
- U.S. sites
- 9
- U.S. states
- 2
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Corona | Corona | California | 92879 | — |
| City of Hope Medical Center | Duarte | California | 91010 | — |
| City of Hope Antelope Valley | Lancaster | California | 93534 | — |
| City of Hope Mission Hills | Mission Hills | California | 91345 | — |
| City of Hope Rancho Cucamonga | Rancho Cucamonga | California | 91730 | — |
| City of Hope South Pasadena | South Pasadena | California | 91030 | — |
| City of Hope West Covina | West Covina | California | 91790 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Wilmot Cancer Institute | Rochester | New York | 14642 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03477396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2024 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03477396 live on ClinicalTrials.gov.